|
|
Volumn 103, Issue 20, 2011, Pages 1491-1493
|
|
International cancer conference: Targeted therapies boom expected in 3 - 5 years
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EVEROLIMUS;
IPILIMUMAB;
OCTREOTIDE;
PASIREOTIDE;
PERTUZUMAB;
SOMATOSTATIN DERIVATIVE;
TELOTRISTAT ETIPRATE;
TRASTUZUMAB;
VEMURAFENIB;
VISMODEGIB;
TUMOR MARKER;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER MORTALITY;
CANCER RESEARCH;
CANCER SURVIVAL;
CIRCULATING TUMOR CELL;
CONFERENCE PAPER;
ESOPHAGUS CANCER;
GENE MUTATION;
HUMAN;
LAPAROSCOPIC SURGERY;
MELANOMA;
METASTASIS;
NEUROENDOCRINE TUMOR;
PANCREAS CANCER;
PATIENT CARE;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
ROBOTICS;
THYROID CANCER;
UTERINE CERVIX CANCER;
BLOOD;
BREAST TUMOR;
ESOPHAGUS TUMOR;
EUROPE;
FEMALE;
GENETICS;
GENOTYPE;
METABOLISM;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
NEOPLASM;
NOTE;
ORGANIZATION;
PANCREAS TUMOR;
THYROID TUMOR;
TUMOR EMBOLISM;
UTERINE CERVIX TUMOR;
BREAST NEOPLASMS;
CONGRESSES AS TOPIC;
ESOPHAGEAL NEOPLASMS;
EUROPE;
FEMALE;
GENOTYPE;
HUMANS;
INDIVIDUALIZED MEDICINE;
MELANOMA;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
NEOPLASTIC CELLS, CIRCULATING;
NEUROENDOCRINE TUMORS;
PANCREATIC NEOPLASMS;
THYROID NEOPLASMS;
TUMOR MARKERS, BIOLOGICAL;
UTERINE CERVICAL NEOPLASMS;
|
|
EID: 84856382969
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr414 Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (0)
|
